Auna S.A. (AUNA)vsEli Lilly and Company (LLY)
AUNA
Auna S.A.
$5.17
-0.10%
HEALTHCARE · Cap: $382.87M
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1608% more annual revenue ($79.67B vs $4.67B). LLY leads profitability with a 33.5% profit margin vs 0.3%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 76/100 (B+).
AUNA
Hold49
out of 100
Grade: D+
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.9% — below average capital efficiency
0.3% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AUNA
The strongest argument for AUNA centers on Price/Book. Revenue growth of 13.2% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. A P/E of 86.2x leaves little room for execution misses. Debt-to-equity of 2.01 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
AUNA profiles as a value stock while LLY is a growth play — different risk/reward profiles.
AUNA carries more volatility with a beta of 0.62 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 49/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a leading telecommunications and digital services provider in Latin America, renowned for its comprehensive suite of integrated solutions that enhance connectivity for both residential and business clients. The company delivers a diverse range of high-speed internet, television, and mobile services, underscoring its commitment to innovation and exceptional customer experience. With a strong infrastructure and strategic market positioning, Auna is poised to capitalize on the growing demand for advanced telecommunications services, making it an attractive investment opportunity for institutional investors seeking to engage in the expanding digital economy in the region.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?